Tirzepatide 40mg (Disposable pen)

Tirzepatide 40mg (Disposable pen)



🧬 Tirzepatide – Dual GIP/GLP-1 Receptor Agonist for Metabolic Research

Synonyms: LY3298176, Dual Incretin Analog
CAS Number: 2023788-19-2
Sequence: 39-amino acid linear peptide with C20 fatty diacid moiety
Molecular Weight: ~4813.5 Da
Form: Pre-filled 40mg injectable pen
Purity: ≄98% (HPLC)
Research Use Only. Not for human consumption.

---

Description:
Tirzepatide is a synthetic dual incretin receptor agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual engagement enhances insulin secretion, reduces appetite, and improves metabolic flexibility. The 40mg pre-filled pen format provides high-dose, once-weekly delivery, ideal for advanced metabolic research protocols requiring sustained incretin exposure.

---

āš™ļø Mechanism of Action:

Tirzepatide mimics the body’s natural incretin response to nutrient intake:

• GIPR Activation: Enhances insulin secretion, improves adipocyte insulin sensitivity, and increases adiponectin
• GLP-1R Activation: Delays gastric emptying, suppresses appetite, and reduces glucagon secretion


Together, these pathways produce synergistic effects on glucose regulation, body weight, and lipid metabolism—surpassing the efficacy of GLP-1 agonists alone.

---

šŸ“ˆ Research Applications:

Tirzepatide is under investigation in preclinical and clinical models for:

• Obesity and body composition modulation
• Type 2 diabetes and insulin resistance
• Non-alcoholic fatty liver disease (NAFLD)
• Cardiometabolic risk reduction
• Neuroendocrine signaling and appetite regulation


In clinical trials, Tirzepatide has demonstrated up to 22.5% body weight reduction and superior glycemic control compared to semaglutide, with additional benefits in lipid and inflammatory markers.

---

🧪 Dosing & Handling (Preclinical):

• Formulation: 40mg pre-filled pen
• Half-life: ~5 days (supports once-weekly administration)
• Storage: Refrigerate at 2–8°C; protect from light
• Administration: Subcutaneous injection; rotate sites weekly
• Cycle: 12–72 weeks typical for metabolic remodeling studies


---

šŸ“¦ Packaging & Storage:

Supplied as a sterile, pre-filled 40mg pen for subcutaneous administration. Store refrigerated 2–8°C. Do not freeze. Use aseptic technique. For research use only.

SKU: TRZ-40MG-PEN-DSP
Ā£145.00
5 left